BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25809144)

  • 21. Steroid or calcineurin inhibitor-sparing immunosuppressive protocols.
    Grinyó JM; Cruzado JM
    Contrib Nephrol; 2005; 146():30-42. PubMed ID: 15567918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation.
    Jacquet A; Francois H; Frangie C; Ahmad L; Charpentier B; Durrbach A
    Transpl Immunol; 2008 Nov; 20(1-2):29-31. PubMed ID: 18817870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can the early elimination of calcineurin inhibitors result in clinical benefits?
    Weir MR
    Transplant Proc; 2010 Nov; 42(9 Suppl):S16-20. PubMed ID: 21095444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal immunosuppression to prevent chronic allograft dysfunction.
    Grinyó JM; Bestard O; Torras J; Cruzado JM
    Kidney Int Suppl; 2010 Dec; (119):S66-70. PubMed ID: 21116321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation.
    Wong TC; Lo CM; Fung JY
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):123-136. PubMed ID: 28503959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Operational tolerance: past lessons and future prospects.
    Levitsky J
    Liver Transpl; 2011 Mar; 17(3):222-32. PubMed ID: 21384504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing renal transplant failure.
    Vathsala A
    Ann Acad Med Singap; 2005 Jan; 34(1):36-43. PubMed ID: 15726218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The mechanisms of chronic kidney damage in renal transplant and their possible reversibility].
    Schena FP; Maiorano A; Rossini M
    G Ital Nefrol; 2008; 25 Suppl 44():S11-4. PubMed ID: 19048580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes.
    Baron D; Giral M; Brouard S
    Transpl Int; 2015 Aug; 28(8):938-59. PubMed ID: 25851900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
    Webber AB; Vincenti F
    Transplantation; 2016 Apr; 100(4):836-43. PubMed ID: 27003097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of calcineurin inhibitors on graft survival.
    Rush D
    Transplant Rev (Orlando); 2013 Jul; 27(3):93-5. PubMed ID: 23743217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunosuppression and treatment of graft rejection after kidney transplantation].
    May G
    Urologe A; 1994 Sep; 33(5):365-9. PubMed ID: 7974923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types.
    Perez CP; Patel N; Mardis CR; Meadows HB; Taber DJ; Pilch NA
    Transplantation; 2018 Sep; 102(9):1440-1452. PubMed ID: 29787522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current concepts and perspectives of immunosuppression in organ transplantation.
    Scherer MN; Banas B; Mantouvalou K; Schnitzbauer A; Obed A; Krämer BK; Schlitt HJ
    Langenbecks Arch Surg; 2007 Sep; 392(5):511-23. PubMed ID: 17450373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney transplantation in HIV-positive patients treated with a steroid-free immunosuppressive regimen.
    Bossini N; Sandrini S; Casari S; Tardanico R; Maffeis R; Setti G; Valerio F; Forleo MA; Nodari F; Cancarini G
    Transpl Int; 2014 Oct; 27(10):1050-9. PubMed ID: 24964311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
    Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ
    Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.